Trio

Trio is a large multidomain signaling protein containing two functional Rho-family guanine nucleotide exchange factor (GEF) domains and a C-terminal serine/threonine kinase domain whose sequence is most similar to calcium/calmodulin-dependent kinases^[1]. The kinase domain of TRIO possesses sequence characteristics of the CaMK class but exhibits RhoGEF activity^[1][2]. Mechanistically, GEFD1 activates RAC1 and drives JNK activation and membrane ruffling, whereas GEFD2 preferentially activates RHOA and promotes stress-fiber formation, allowing TRIO to connect RAC1 and RHOA signaling^[2]. These activities coordinate actin-cytoskeleton remodeling, neuronal migration, axonal outgrowth, axon guidance, and synaptogenesis^[3]. Pathogenic TRIO variants cause domain-specific neurodevelopmental phenotypes: spectrin-repeat variants increase RAC1 activity and are associated with more severe intellectual disability and macrocephaly, whereas GEFD1 variants reduce RAC1 activation and commonly associate with milder intellectual disability and microcephaly^[3]. TRIO also produces nervous-system-enriched alternative isoforms containing one or two RhoGEF domains, and GEFD1-containing isoforms promote neurite outgrowth in neuroblastoma cells^[4]. Full-length TRIO is broadly expressed, whereas these alternatively spliced isoforms are preferentially expressed in the nervous system, emphasizing isoform-specific experimental interpretation^[4]. For experimental studies, ITX3 selectively inhibits the N-terminal TrioN GEF pathway, blocking Trio-mediated RAC1 activation and neurite outgrowth without targeting the kinase domain^[5].